Matrine attenuates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via maintaining AMPKα/UCP2 pathway

Can Hu, Xin Zhang, Wenying Wei, Ning Zhang, Haiming Wu, Zhenguo Ma, Lingli Li, Wei Deng, Qizhu Tang

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China
Hubei Key Laboratory of Cardiology, Wuhan 430060, China

Received 11 January 2019; received in revised form 2 February 2019; accepted 11 March 2019

Abstract Oxidative stress and cardiomyocyte apoptosis are involved in the pathogenesis of doxorubicin (DOX)-induced cardiotoxicity. Matrine is well-known for its powerful anti-oxidant and anti-apoptotic capacities. Our present study aimed to investigate the effect of matrine on DOX-induced cardiotoxicity and try to unearth the underlying mechanisms. Mice were exposed with DOX to generate DOX-induced cardiotoxicity or normal saline as control. H9C2 cells were used to verify the effect of matrine in vitro.

DOX injection triggered increased generation of reactive oxygen species (ROS) and excessive cardiomyocyte apoptosis, which were significantly mitigated by matrine. Mechanistically, we found that matrine ameliorated DOX-induced uncoupling protein 2 (UCP2) downregulation, and UCP2 inhibition by exogenous ROS could reverse the protective effect of matrine. Furthermore, AMPKα phosphorylation was significantly increased by matrine treatment, and AMPKα inhibition could abolish the protective effect of matrine.

Abbreviations: 4-HNE, 4-hydroxynonenal; ACC, acetyl-CoA carboxylase; AMPKα, 5'-AMP-activated protein kinase α; ANOVA, analysis of variance; BAX, BCL-2-associated X protein; BCL-2, B-cell lymphoma 2; C-caspase 3, cleaved-caspase 3; CCK-8, cell counting kit 8; CK-MB, creatine kinase isoenzymes; cTnT, cardiac isoform of Troponin T; DCFH-DA, 2',7'-dichlorodihydrofluorescein diacetate; DHE, dihydroethidium; DMEM, Dulbecco’s modified Eagle’s medium; DOX, doxorubicin; FBS, fetal bovine serum; FS, fractional shortening; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HW, heart weight; LDH, lactate dehydrogenase; MDA, malondialdehyde; MDA, malondialdehyde; BCA, bicinchoninic acid; PPARs, peroxisomal proliferators-activated receptors; ROS, reactive oxygen species; SOD2, superoxide dismutase 2; T-caspase 3, total-caspase 3; TL, tibia length; Top2, topoisomerase-II; TUNEL, TdT-mediated dUTP nick end-labelling; UCP2, uncoupling protein 2

*Corresponding authors. Tel.: +86 27 88073385; fax: +86 27 88042292.
E-mail addresses: vivideng1982@whu.edu.cn (Wei Deng), qztang@whu.edu.cn (Qizhu Tang).
†These authors made equal contributions to this work.

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
genipin could blunt the protective effect of matrine on DOX-induced oxidative stress and cardiomyocyte apoptosis. Besides, 5'-AMP-activated protein kinase α2 (AMPKα2) deficiency inhibited matrine-mediated UCP2 preservation and abolished the beneficial effect of matrine in mice. Besides, we observed that matrine incubation alleviated DOX-induced H9C2 cells apoptosis and oxidative stress level via activating AMPKα/UCP2, which were blunted by either AMPKα or UCP2 inhibition with genetic or pharmacological methods. Matrine attenuated oxidative stress and cardiomyocyte apoptosis in DOX-induced cardiotoxicity via maintaining AMPKα/UCP2 pathway, and it might be a promising therapeutic agent for the treatment of DOX-induced cardiotoxicity.

1. Introduction

Doxorubicin (DOX) is a widely used and highly potent chemotherapy agent to treat various types of cancers. However, the clinical usage of DOX is greatly limited by its dose-dependent cardiotoxicity, which eventually leads to irreversible degenerative cardiomyopathy and congestive heart failure. Despite the limited elucidation of pathogenesis of DOX-induced cardiotoxicity, accumulating evidence suggested that excessive production of ROS is the main factor involved in DOX-induced cardiotoxicity, which leads to oxidative damage and cardiomyocyte apoptosis, and eventually the occurrence of heart failure.

Mitochondria are the major source of intracellular ROS. The excessive production of ROS induces oxidative damage to biological macromolecules, including lipids, proteins and DNA, and disrupts cellular membrane structure and functions. Mitochondrial uncoupling proteins (UCPs) are now well accepted as predominant type of UCPs in the heart. Previous studies showed that Ucp2 deficiency exacerbated oxidative stress and delayed liver regeneration in mice, whereas adenovirus-mediated UCP2 overexpression inhibited ROS production and protected endothelial cells from oxidative damage. Besides, activation of UCP2 allowed for the prevention of ischemia-reperfusion induced oxidative stress and preservation of mitochondrial function. Previously, Dhamrait et al. reported that gene mutation of UCP2 in man that led to a decreased UCP2 expression could reduce total antioxidant status. More importantly, a recent study demonstrated that knockdown of UCP2 could exacerbate DOX-induced cardiomyocyte apoptosis and myocardial oxidative stress.

5'-AMP-activated protein kinase α (AMPKα) is a highly conserved eukaryotic serine/threonine protein kinase, and exerts beneficial effects in many physiological and pathological process, including energy homeostasis, endoplasmic reticulum stress, cardiac hypertrophy and fibrosis, etc. Current available studies showed that AMPKα also played essential roles in regulating oxidative stress and cell survival. Kim et al. found that AMPKα activation decreased iron-induced ROS production and inhibited cell apoptosis. Ceolotto et al. further confirmed that activation of AMPKα prevented hyperactivity of NADPH oxidase and protected endothelial cells against glucose-induced oxidative damage. All these data defined indispensable roles of UCP2 and AMPKα in the regulation of oxidative stress and cell apoptosis. Therefore, targeting AMPKα and UCP2 may be of great therapeutic interest for the treatment of DOX-induced cardiotoxicity.

Matrine, a natural compound extracted from the root of Sophora flavescens Ait, has been shown several pharmacological activities, including anti-inflammatory, anti-fibrotic capacities, and served as a therapeutic agent clinically for the treatment of viral hepatitis and dementia. Previous studies showed that matrine and its derivatives reduced inflammatory response and attenuated sepsis-induced organ injury. In addition, Liu et al. implied that matrine treatment increased the expression of NF-E2-related factor 2 and heme oxygenase-1, and suppressed ROS production in experimental autoimmune encephalomyelitis. Moreover, matrine administration resulted in an apparent decrease of ROS formation and prevented cardiomyocyte apoptosis in diabetic hearts. Based on these data, we suppose that matrine might be a promising therapeutic agent against DOX-induced cardiotoxicity. Therefore, the present study aimed to evaluate the protective effect of matrine on DOX-induced cardiotoxicity and tried to elucidate the underlying mechanisms.

2. Materials and methods

2.1. Reagents and antibodies

Matrine (M5319), DOX (D1515) and genipin (G4796) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Primary antibodies for the following proteins were purchased from Cell Signaling Technology (Danvers, MA, USA): UCP2 (1:1000), total-caspase3 (T-caspase3, 1:1000), cleaved-caspase3 (C-caspase3, 1:1000), BCL-2-associated X protein (BAX, 1:1000), T-AMPKα (1:1000), phosphorylated-AMPKα (P-AMPKα, 1:1000), T-acetyl-CoA carboxylase (T-ACC, 1:1000), p-ACC (1:1000) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:1000). Anti-B-cell lymphoma 2 (BCL-2, 1:1000), superoxide dismutase 2 (SOD2, 1:1000) and 4-hydroxynonenal (4-HNE, 1:200 for staining) were obtained from Abcam (Cambridge, UK). Dihydroethidium (DHE) was obtained from Keygen Biotech (Nanjing, China), and 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) was purchased from Beyotime Biotechnology (Shanghai, China). Malondialdehyde (MDA) assay kit, total SOD assay kit and NADPH oxidase assay kit were all purchased from Nanjing Jiancheng.
Bioengineering Institute (Nanjing, China). The cell counting kit-8 (CCK-8) was obtained from Düjindo Laboratories (Kumamoto, Japan). ApopTag® Plus In Situ Apoptosis Fluorescein Detection Kit was purchased from Millipore (Billerica, MA, USA). Small interfering RNA against UCP2 (siUCP2) and its negative control (siRNA) were synthesized by RiboBio (RiboBio Co. Ltd, Guangzhou, China). Replication-defective adeno-vectors carrying small hairpin RNA against *Ampkα2* (sh*Ampkα2*) were obtained from Vigene Bioscience (Rockville, MD, USA), and the efficiency was confirmed by western blot as previously described. Anti-rabbit/mouse EnVision™/HRP reagent was purchased from Gene Technology (Shanghai, China). The bichinchoninic acid (BCA) protein assay kit was obtained from Pierce (Rockford, IL, USA).

### 2.2 Animals and treatment

All animal care and experimental procedures were approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University (Wuhan, China) and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication, revised 2011). Adult male C57/B6 mice (weight: 23.5–27.5 g, age: 8–10 weeks) were purchased from the Laboratory of the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (Beijing, China). Mice were bred in the specific pathogen free conditions with a controlled temperature (20–25 °C) and suitable humidity (50 ± 5%). The animals were allowed free access to food and water, and were housed with regular 12/12 h light/dark cycles. After an adaptive feeding for 1 week, the mice were randomly exposed to intraperitoneal injections of DOX (4 mg/kg) weekly for consecutive 4 weeks to generate DOX-induced cardiotoxicity or equal volume of normal saline (NS) as a control. To investigate the effect of matrine, mice were intragastrically administered with matrine (200 mg/kg/day) simultaneously from the first injection of DOX referring to previous studies. All the mice were monitored and weighed weekly, and were sacrificed after 4-week matrine treatment, with hearts collected for further experiment. For UCP2 inhibition, genipin (30 mg/kg) was administered biweekly by intraperitoneal injection for two times referring to previous data. To verify the involvement of AMPKα, *Ampkα2* knockout (KO) mice were used, and the source has been described in our previous studies.

### 2.3 Echocardiography and hemodynamics

Echocardiography and invasive hemodynamic monitoring were performed referring to our previous studies. Briefly, mice were lightly anaesthetized with isoflurane (1.5%) and subjected to a MyLab 30CV ultrasound (Esaote SpA, Genoa, Italy) to detect the morphological and functional parameters of the heart, averaged from three to five cardiac cycles. Hemodynamic variables were collected by the PowerLab system (AD Instruments Ltd., Oxford, UK) using a 1.4-French Millar pressure-volume catheter (SPR-839; Millar Instruments, Houston, TX) and the data were analyzed using the PVAN data analysis software.

### 2.4 Immunohistochemistry staining

The paraffin-embedded heart sections were dewaxed, rehydrated and incubated with citric acid buffer for antigen retrieval, and then they were treated with 3% hydrogen peroxide and 10% goat serum to block endogenous peroxidase and the nonspecific binding of the antibody. After incubated with primary antibodies against 4-HNE (1:100) at 4 °C overnight, sections were incubated with anti-rabbit/mouse EnVision™/HRP reagent for 1 h at 37 °C. After being visualized with diaminobenzidin for 2 min at room temperature, these sections were observed and analyzed by two investigators in a blinded manner.

### 2.5 Western blot and quantitative real-time PCR

Western blot and quantitative real-time PCR were performed according to our previous studies. Total proteins were extracted from murine hearts or cell lysates, and the protein concentration was determined by BCA protein assay kit. Then, the proteins were separated on 10% SDS-PAGE and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA; No. IPFL00010). Membranes were blocked with 5% skim milk for 1 h at room temperature, and incubated with the primary antibodies at 4 °C overnight followed with the secondary antibodies for an additional 1 h. The images were detected and quantified by Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Total RNA was extracted using TRIzol reagent and reverse transcribed with Maxima First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland; 04896866001). The expression level of each individual transcript was normalized to *Gapdh*.

### 2.6 Cell culture and treatment

H9C2 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO, USA) with 10% fetal bovine serum (FBS, GIBCO, USA). After being starved for 16 h to synchronize, H9C2 cells were assigned randomly to incubate with matrine (200 μmol/L) or equal volume of vehicle in the presence or absence of DOX (1 μmol/L) for 24 h. To knock down the expression of UCP2 in *vitro*, cells were transfected with siUCP2 (50 nmol/L) for 24 h using Lipo6000™ transfection reagent (Beyotime, Shanghai, China) according to the manufacturer's protocol as our previous described. The efficiency was confirmed by western blot, and we chose the most effective sequence for further study. To evaluate the role of AMPKα in matrine-mediated protective effects, we knocked down AMPKα with sh*Ampkα2* as previously described. The efficiency was determined with western blot. Cell viability was detected by CCK-8 according to the protocol.

### 2.7 Oxidative stress detection in vivo and in vitro

ROS generation was detected by DHE staining in *vivo* and DCFH-DA staining in *vitro*. Briefly, frozen heart sections or H9C2 cells were incubated with DHE (5 μmol/L) or DCFH-DA (5 μmol/L) at 37 °C for 30 min in a dark chamber. Fluorescent images were observed with a fluorescence microscope (Olympus IX53, Tokyo, Japan) in a blinded manner. To further assess oxidative stress level, the content of MDA, total SOD activity and NADPH oxidase activity in the myocardium or H9C2 cells were measured according to our previous study by commercially available kits.

### 2.8 TdT-mediated dUTP nick end-labelling (TUNEL) staining

A commercially available kit was used to detect apoptosis levels in *vivo* and *in vitro* as we previously described, and the images were captured via the OLYMPUS DX51 fluorescence microscope (Tokyo, Japan).
2.9. Biochemical analysis

Serum levels of cardiac isoform of Troponin T (cTnT), lactate dehydrogenase (LDH) and creatine kinase isoenzymes (CK-MB) were measured by an automatic biochemical analyzer (ADVIA 2400, Siemens Ltd., China) as previously described37.

2.10. Statistical analysis

All data in this research were presented as mean $\pm$ standard error of the mean (SEM) and analyzed using SPSS 22.0 software. One-way analysis of variance (ANOVA) followed by Tukey post hoc test was performed when comparing multiple groups, whereas differences in two groups were evaluated using unpaired Student’s $t$-test. A value of $P<0.05$ was considered statistically significant.

3. Results

3.1. Matrine attenuated DOX-induced cardiotoxicity in mice

Mice were challenged with DOX (4 mg/kg, i.p.) weekly for consecutive 4 weeks to generate DOX-induced cardiotoxicity. As shown in Fig. 1A–C, DOX injection significantly impaired the left ventricular function as indicated by the decreased fractional shortening (FS) and $+dP/dt$, which were significantly attenuated by matrine administration. However, matrine treatment alone showed no beneficial effects on heart function under basal conditions (Fig. 1A–C). Consistent with the fact that DOX injection results in massive loss of cardiac cells, we observed that heart weight (HW) / tibia length (TL) was markedly decreased in DOX-treated mice, which was mitigated with matrine protection (Fig. 1D). Previous studies indicated that chemotherapeutic agents-induced body weight loss predicted bad prognosis in cancer patients and DOX clinical usage is usually accompanied with decreased body weight38,39. Our present data suggested that systematic administration of matrine prevented DOX-induced body weight loss in mice (Fig. 1E). Matrine also overtly decreased the mRNA levels of Anp and Bnp in DOX-treated murine hearts (Fig. 1F). Myocardial injury was also assessed by the serum levels of cTnT, LDH and CK-MB, and we observed that matrine alleviated DOX-induced myocardial injury (Fig. 1G). Collectively, we concluded that matrine attenuated DOX-induced cardiotoxicity in mice.

3.2. Matrine prevented oxidative damage in response to DOX insult

Oxidative stress has been proved to be the primary mechanism in DOX-induced cardiotoxicity, which eventually resulted in massive cardiomyocyte apoptosis4. As shown in Fig. 2A and B, matrine administration decreased lipid peroxidation and ROS generation in
DOX-treated murine hearts. Western blot results also verified the protective effect of matrine on DOX-induced oxidative stress, as confirmed by the decreased p67phox and increased SOD2 protein levels (Fig. 2C and D). We also observed that matrine administration reduced the abnormal MDA level and NADPH oxidase activity, and preserved total SOD activity (Fig. 2E). Such results were further confirmed by the mRNA levels of p67phox, Gp91phox and Sod2 (Fig. 2F). All these data defined a beneficial effect of matrine on DOX-induced oxidative damage.

3.3. Matrine attenuated DOX-induced cardiomyocyte apoptosis

Cardiomyocyte apoptosis is an important event in the process of DOX-induced cardiotoxicity and contributes to the progression of cardiac dysfunction. Consistently, we found that DOX injection resulted in distinct cardiomyocyte apoptosis, which was significantly alleviated in mice with matrine protection (Fig. 3A and B). The protective effect on apoptosis was further confirmed by Western blot data showing that matrine decreased the expression of BAX, C-caspase3 and increased the BCL-2 level after DOX treatment (Fig. 3C and D).

3.4. UCP2 was responsible for matrine-mediated beneficial effect on DOX-induced cardiotoxicity

UCP2 is known to restrain ROS generation, and UCP2 knockdown exacerbated DOX-induced oxidative stress and cell death. Consistent with previous studies, we observed that myocardial expression of UCP2 was downregulated by DOX, which was alleviated in mice with matrine protection (Fig. 4A). To further elucidate the role of UCP2 in matrine-mediated protective effects in vivo, we treated mice with genipin, an inhibitor of UCP2. As shown in Fig. 4B–G, UCP2 inhibition almost completely abolished matrine-induced downregulation of p67phox, Gp91phox and Sod2 (Fig. 4F). All these data defined a beneficial effect of matrine on DOX-induced oxidative damage.

3.5. Knockdown of UCP2 blunted the protective effects of matrine in vitro

To investigate whether Ucp2 deficiency could blunt the protective effects of matrine on oxidative stress and cardiomyocyte apoptosis in vitro, we knocked down the expression of UCP2 in H9C2 cells via siUcp2 and the efficiency was confirmed by
Matrine attenuates doxorubicin-induced cardiotoxicity

695

Western blot (Fig. 5A). Consistent with the data in vivo, we found that the inhibitory effect of matrine on ROS generation was blunted after the knockdown of UCP2 (Fig. 5B). Besides, matrine lost its effect on DOX-induced cardiomyocyte apoptosis in Ucp2-knockdown cells, as confirmed by the cell viability assay and TUNEL staining (Fig. 5C–D). Western blot results further confirmed that matrine-induced downregulation of p67phox, BAX, and C-caspase3, as well as upregulation of SOD2 and BCL-2, was counteracted in the absence of UCP2 (Fig. 5E–J). In line with the molecular alterations, we found that matrine alleviated DOX-induced oxidative stress and cardiomyocyte apoptosis via preserving the expression of UCP2.

3.6. Matrine prevented DOX-induced downregulation of UCP2 via activating AMPKα

We next explored the possible mechanism by which matrine prevented DOX-induced downregulation of UCP2. Previous studies implied that AMPKα was inactivated in response to DOX treatment. More importantly, Ampkα silence reduced UCP2 level, whereas Ampkα activation increased the expression of UCP2. Therefore, we speculated that matrine might prevent DOX-induced downregulation of UCP2 via activating AMPKα.

As expected, we found that matrine treatment restored the decreased AMPKα activity induced by DOX incubation in H9C2 cells, which was further assessed by the increased phosphorylation of ACC (Fig. 6A and B). To gain evidence that AMPKα was responsible for the upregulation of UCP2, we knocked down Ampkα with adenoviruses in H9C2 cells, and the efficiency was evidenced by Western blot (Supporting Information Fig. S1). As shown in Fig. 6C and D, Ampkα knockdown abolished the restoration of UCP2 level by matrine in vitro. In line with the downregulation of UCP2, we found that Ampkα knockdown significantly abrogated matrine-mediated inhibitory effect on ROS generation and oxidative stress level (Fig. 6E–G), as well as the content of MDA, NADPH oxidase activity and total SOD activity (Fig. 6H). Besides, the protective effect of matrine on cardiomyocyte injury was also blunted, as evidenced by the cell viability, apoptosis-related proteins and serum LDH level (Fig. 6I–M). Therefore, we concluded that matrine prevented DOX-induced downregulation of UCP2 via activating AMPKα.

3.7. Ampkα deficiency abolished the protective effect of matrine in vivo

To further investigate whether matrine exerted its protective effects through AMPKα/UCP2 pathway axis in vivo, Ampkα2 KO mice were used. Consistent with the data in vitro, we observed that Ampkα deletion suppressed matrine-induced upregulation of UCP2 in murine hearts (Fig. 7A). Besides, matrine-mediated downregulation of p67phox, BAX, and C-caspase3, as well as upregulation of SOD2 and BCL-2, was all reversed by Ampkα deletion (Fig. 7C and D). In line with the molecular alterations, matrine lost its protective effects on oxidative stress and cardiomyocyte apoptosis in Ampkα-deficient mice, as evidenced by the unaltered MDA level, SOD activity and serum myocardial injury markers (Fig. 7E–F). More importantly, we found that matrine could attenuate DOX-induced cardiac dysfunction in wild type mice, but not in Ampkα-deficient mice (Fig. 7G). The protective effect of matrine on HW/TL was also abolished in Ampkα-deficient mice (Fig. 7H). Collectively, these results suggested that the protective effects of matrine on oxidative stress and cardiomyocyte apoptosis were dependent on the activation of AMPKα/UCP2 axis.

Figure 3 Matrine attenuated DOX-induced cardiomyocyte apoptosis. (A) and (B) Representative TUNEL staining images and the quantitative results for apoptosis in heart tissues (n = 6). (C) and (D) Western blot and statistical results in the indicated groups (n = 6). Red arrows indicate TUNEL positive staining. Values represent the mean ± SEM. *P < 0.05 versus NS+Vehicle; #P < 0.05 versus DOX+Vehicle.
4. Discussion

DOX significantly increased the survival rate of cancer patients; nevertheless, many survivors suffer from DOX-induced cardiotoxicity with left ventricular dysfunction and heart failure, which markedly reduced the quality of life for survivors. Thus, a promising pharmacological therapy for DOX-induced cardiotoxicity is urgently needed to be addressed. In this study, we determined that matrine attenuated DOX-induced cardiotoxicity via inhibiting oxidative stress and cardiomyocyte apoptosis. Mechanistically, we found that matrine suppressed UCP2 downregulation in DOX-treated murine hearts, thus exerted beneficial effects on oxidative stress and cardiomyocyte apoptosis. And we also verified that AMPK activation was responsible for restoring the expression of UCP2. Either AMPK deletion or UCP2 inhibition with genetic or pharmacological methods abrogated matrine-mediated beneficial effects on oxidative stress and cardiomyocyte apoptosis both in vivo and in vitro. Therefore, our present study identified matrine as a promising therapeutic agent against DOX-induced cardiotoxicity.

Increased oxidative damage due to ROS overproduction has been actually implicated in the progression of DOX-induced cardiotoxicity. Excessive ROS generation may cause DNA damage, mitochondrial dysfunction and protein synthesis inhibition, which were linked to the activation of apoptotic cascades and ultimately contribute to heart failure. Zhu et al. found that

**Figure 4** UCP2 was responsible for matrine-mediated beneficial effect on DOX-induced cardiotoxicity. (A) UCP2 expression level in murine hearts with or without DOX or matrine (n = 6; *P < 0.05 versus NS+Vehicle, #P < 0.05 versus DOX+Vehicle). (B)-(G) Western blot and statistical results in the indicated groups (n = 6). (H) Relative mRNA levels of p67phox, Gp91phox and Sod2 (n = 6). (I) The content of MDA, NADPH oxidase activity and total SOD activity in the myocardium (n = 6). (J)-(K) Plasma levels of cTnT and LDH (n = 6). Values represent the mean ± SEM. *P < 0.05 versus the matched groups.
dietary nitrate supplementation decreased oxidative damage and protected against DOX-induced cardiomyopathy in mice. Moreover, Zhang et al. previously defined topoisomerase-II β (Top2β) as an essential driver of DOX-induced oxidative stress and cardiomyocyte apoptosis. DOX application suppressed DNA replication and resulted in cell cycle arrest and apoptosis of cancer cells when binding to Top2α. However, when DOX bound to Top2β, it increased ROS generation, impaired mitochondrial function and triggered cardiomyocyte apoptosis for the absence of Top2α and the abundance of Top2β within the heart. These findings collectively suggested that oxidative damage was responsible for the occurrence of DOX-induced cardiac dysfunction. Accordingly, targeting oxidative stress, many cardioprotective agents including N-acetylcystiene, angiotensin converting enzyme inhibitors and statins have been tested in clinical trials with some efficacy for recovery of cardiac function but are not used prophylactically. Dexrazoxane is the only cardioprotective agent proven to be effective in the prevention and treatment of DOX-induced cardiotoxicity. It is regarded as a derivative of EDTA and can decrease ROS generation through its iron chelating activity.

Figure 5  Knockdown of UCP2 blunted the protective effects of matrine in vitro. (A) Western blot for UCP2 and the quantitative data for H9C2 cells (n = 6). (B) Representative DCFH-DA images and the statistical results. (C) CCK-8 assay for cell viability (n = 5). (D) Representative images of TUNEL in H9C2 cells (n = 5). (E)–(J) Western blot and statistical results (n = 6). (K) The content of MDA, NADPH oxidase activity and total SOD activity in H9C2 cells (n = 5). (L) LDH levels in H9C2 cells (n = 5). Red arrows indicate TUNEL positive staining. Values represent the mean ± SEM. *P < 0.05 versus the matched groups. NS indicates no statistical difference.
resulted in severe side effects, such as hepatic toxicity, early death, etc. Furthermore, dexrazoxane also depletes Top2α and may reduce its chemotherapeutic capacities48. In the present study, we found that matrine prevented DOX-induced oxidative stress and cardiomyocyte apoptosis both in vivo and in vitro, and matrine administration attenuated cardiac dysfunction in response to DOX insult. More importantly, matrine has been clinically used for the treatment of hepatic tumors in the form of capsule or injection solution with little adverse effects (China Food and Drug Administration approvals H20010242 or H20044669; China Food and Drug Administration, 2014)29,49. In addition, numerous studies implied that matrine or its derivative WM130 showed beneficial effects on other cancer cells in basic experiment50–52. All these data proved that matrine could be an effective and safe therapeutic agent against DOX-induced cardiotoxicity.

UCP2 is increasingly recognized as an important target to restrain oxidative damage in the pathologic processes of various cardiovascular diseases, including atherosclerosis, hypertension and cardiac injury53. UCP2 exerted its protective effects on oxidative stress via uncoupling of respiration, that is, uncoupling oxygen consumption from ATP synthesis54. Previously, Teshima et al.55 found that UCP2 overexpression reduced ROS production in mitochondria and protected cardiomyocytes from oxidative stress-induced cell death. In addition to its antioxidant effect, Turner et al.10 also demonstrated that UCP2 overexpression markedly inhibited mitochondrial Ca2+ uptake and significantly prolonged the contractile effect. Recent studies indicated that myocardial UCP2 expression was downregulated in response to DOX and Ucp2 deficiency further exacerbated DOX-induced oxidative stress and cardiomyocyte apoptosis40. In this study, we observed that matrine alleviated oxidative damage and cardiomyocyte apoptosis via preventing DOX-induced downregulation of UCP2, whereas pharmacological inhibition or genetic deletion of UCP2 abolished the beneficial effects both in vivo and in vitro. UCP2 protein expression has been proved to be regulated at multiple levels, and we found that AMPKα activation was responsible for matrine-mediated upregulation of UCP2, which is consistent with previous studies56,57. Long-chain fatty acid was the first described transcriptional activators of Ucp2. Reilly et al.58 and Samec et al.59 found that polyunsaturated fatty acids triggered UCP2 upregulation in 3T3-L1 preadipocytes. One possible candidate for transcriptional activation of Ucp2 by long-chain fatty acid is peroxisomal proliferators-activated receptors (PPARs); however, no such PPAR response elements have been annotated within or in vicinity of the Ucp2 gene. All this suggested that PPAR-mediated regulation of UCP2 appeared to be indirect60. AMPKα is a key controller of energy metabolism and survival during cellular stress, and plays a critical role in regulating lipid metabolism via PPAR-dependent or PPAR-independent manners61. Despite the exact mechanism through which AMPKα activation increases UCP2 expression remains unclear, previous studies also indicated that AMPKα activation increased the expression of UCP2, which is in line with our present study.

5. Conclusions

The present study found that matrine administration attenuated DOX-induced cardiotoxicity via suppressing oxidative stress and
cardiomyocyte apoptosis. Matrine treatment resulted in AMPKα activation and subsequently upregulated UCP2 expression to restrain ROS generation and oxidative damage. Our data identified matrine as a promising therapeutic agent for the treatment of DOX-induced cardiotoxicity.

Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (Nos. 81470516 and 81500184), the Key Project of the National Natural Science Foundation (No. 81530012, China), the Fundamental Research Funds for the Central Universities (Nos. 2042017k00085 and 2042015k0073, China) and Scientific Action Plans for the Prevention and Treatment of Major Diseases-Cardiovascular Diseases (2016ZX-008-01, China).

Appendix A. Supporting information

Supporting data associated with this article can be found in the online version at https://doi.org/10.1016/j.apsb.2019.03.003.

References

1. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267–85.
2. Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, et al. Phosphoinositide 3-Kinaseγ inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 2018;138:696–711.
3. Yamanaka S, Tatsumi T, Shiraiishi J, Mano A, Keira N, Matoba S, et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 2003;41:870–8.
4. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. *Circulation* 2003;107:906–904.

5. Wang W, Fang H, Groom L, Cheng A, Zhang W, Liu J, et al. Superoxide flashes in single mitochondria. *Cell* 2008;134:279–90.

6. Battogtokh G, Choi YS, Kang DS, Park SJ, Shim MS, Huh KM, et al. Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives. *Acta Pharm Sin B* 2018;8:862–80.

7. Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. *Nat Rev Mol Cell Biol* 2005;6:248–61.

8. Zhang X, Zhang X, Zhang Y, Liu M, Jin J, Yan J, et al. Mitochondrial uncoupler triocilans induces vasorelaxation of rat arteries. *Acta Pharm Sin B* 2017;7:623–9.

9. Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCPC2 and UCPC3. *Cell Metab* 2005;5:85–93.

10. Turner JD, Gaspers LD, Wang G, Thomas AP. Uncoupling protein-2 modulates myocardial excitation-contraction coupling. *Circ Res* 2010;106:730–8.

11. Horimoto M, Fulop P, Derdak Z, Wands JR, Bafy G. Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. *Hepatology* 2004;39:386–92.

12. Lee KU, Lee IK, Han J, Song DK, Kim YM, Song HS, et al. Effects of recombinant adenosine-mediated uncoupling protein 2 overexpression on endothelial function and apoptosis. *Circ Res* 2005;96:1200–7.

13. Chen K, Xu Z, Liu Y, Wang Z, Li Y, Xu X, et al. Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury. *Sci Transl Med* 2017;9:1–32.

14. Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, et al. Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. *Eur Heart J* 2004;25:468–75.

15. Yao F, Zhang M, Chen L. 5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications. *Acta Pharm Sin B* 2016;6:20–5.

16. Steinberg GR, Kemp BE. AMPK in health and disease. *Physiol Rev* 2009;89:1025–78.

17. Li J, Zhong L, Wang F, Zhu H. Dissecting the role of AMP-activated protein kinase in human diseases. *Acta Pharm Sin B* 2017;7:249–59.

18. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature* 2012;485:661–5.

19. Morrell M, Burgos JJ, Gonano LA, Vila PM. AMPK-dependent nitric oxide release provides contractile support during hypoperfusion stress. *Basic Res Cardiol* 2017;112:17–8.

20. Kim YW, Lee SM, Shin SM, Hwang SJ, Brooks JS, Kang HE, et al. Efficacy of safinamide as a novel AMPK-activating ligand for preventing iron-induced oxidative stress and liver injury. *Free Radiic Biol Med* 2009;47:1082–92.

21. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. *Arterioscler Thromb Vasc Biol* 2007;27:2627–33.

22. Xu WH, Hu HG, Tian Y, Wang SZ, Li J, Li JZ, et al. Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis. *Hepatology* 2014;60:648–660.

23. Zhou H, Xu M, Gao Y, Deng Z, Cao H, Zhang W, et al. Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor. *Mol Cancer* 2014;13:59–70.

24. Xu J, Wang KQ, Xu WH, Li YH, Qi Y, Wu HY, et al. The matrine derivate MASM prolongs survival, attenuates inflammation, and reduces organ injury in murine established lethal sepsis. *J Infect Dis* 2016;214:1762–72.

25. Liu N, Kan QC, Zhang XJ, Xv YM, Zhang S, Zhang GX, et al. Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis. *Exp Mol Pathol* 2014;97:470–6.

26. Liu ZW, Wang JK, Qiu C, Guan GC, Liu XH, Li SJ, et al. Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway. *Acta Pharmacol Sin* 2015;36:323–33.

27. Zhang X, Ma ZG, Yuan YP, Xu SC, Wei WY, Song P, et al. Rosmarinic acid attenuates cardiac fibrosis following long-term pressure overload via AMPKα/Smad3 signaling. *Cell Death Dis* 2018;9:102–16.

28. Ma ZG, Yuan YP, Xu SC, Wei WY, Xu CR, Zhang X, et al. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. *Diabetologia* 2017;60:1126–1137.

29. Zeng XY, Wang H, Bai F, Zhou X, Li SP, Ren LP, et al. Identification of matrine as a promising novel drug for hepatic steatosis and glucose intolerance with HSF72 as an upstream target. *Br J Pharmacol* 2015;172:4303–18.

30. Dando I, Pachciana R, Pozza ED, Cataldo I, Bruno S, Contri P, et al. CTRP2 inhibition induces ROS/Akt/mTOR axis; role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism. *Free Radic Biol Med* 2017;113:176–89.

31. Zhang N, Yang Z, Xiang SZ, Jin YG, Wei WY, Bian YZ, et al. Nobelin determines cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin-induced diabetic cardiomyopathy. *Mol Cell Biochem* 2016;417:87–96.

32. Guo S, Gao C, Xiao W, Zhang J, Qu Y, Li J, et al. Matrine protects cardiomyocytes from ischemia/reperfusion injury by regulating HSP70 expression via activation of the JAK2/STAT3 pathway. *Shock* 2018;50:664–70.

33. Yuan YP, Ma ZG, Zhang X, Xu SC, Zeng XF, Yang Z, et al. CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1. *J Mol Cell Cardiol* 2018;114:38–47.

34. Ma ZG, Dai J, Wei WY, Zhang WB, Xu SC, Liao HH, et al. Asiatic acid protects against cardiac hypertrophy through activating AMPKε signalling pathway. *Int J Biol Sci* 2016;12:861–71.

35. Liao HH, Zhu JX, Feng H, Ni J, Zhang N, Chen S, et al. Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IκBα/NF-kB and Enhancing Nrf2/HO-1. *Oxid Med Cell Longev* 2017;2017:1–14.

36. Wei WY, Ma ZG, Zhang N, Xu SC, Yuan YP, Zeng XF, et al. Overexpression of CTRP3 protects against sepsis-induced myocardial dysfunction in mice. *Mol Cell Endocrinol* 2018;476:27–36.

37. Wang Z, Wang M, Liu J, Ye J, Jiang H, Xu Y, et al. Inhibition of TRPA1 attenuates doxorubicin-induced acute cardiotoxicity by suppressing oxidative stress, the inflammatory response, and endoplasmic reticulum stress. *Oxid Med Cell Longev* 2018;2018:1–9.

38. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with inflammation, acute-phase response, resting energy expenditure and cachexia of acid-sensitive transferrin and albumin. *J Nutr Biochem* 2018;50:25–34.

39. Wang S, Song P, Zou MH. Inhibition of AMP-activated protein kinase alpha (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. *J Biol Chem* 2012;287:8001–12.

40. Liu L, Liu J, Gao Y, Xu X, Gu G, Huang Y. Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets. *Br J Pharmacol* 2014;171:5246–54.
Matrine attenuates doxorubicin-induced cardiotoxicity

43. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med* 2012;18:1639–42.

44. Tsutsui H, Ide T, Shiomi T, Kang D, Hayashidani S, Suematsu N, et al. 8-oxo-dGTPase, which prevents oxidative stress-induced DNA damage, increases in the mitochondria from failing hearts. *Circulation* 2001;104:2883–5.

45. Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L. Dietary nitrate supplementation protects against doxorubicin-induced cardiomyopathy by improving mitochondrial function. *J Am Coll Cardiol* 2011;57:2181–9.

46. Chakrabarti KB, Hopewell JW, Wilding D, Plowman PN. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dextrazoxane). *Eur J Cancer* 2001;37:1435–42.

47. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga PS, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J Clin Investig* 2014;124:617–30.

48. Rao VA. Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. *Antioxid Redox Signal* 2013;18:930–55.

49. Liu J, Zhu M, Shi R, Yang M. Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. *Am J Chin Med* 2003;31:337–54.

50. Cho YR, Lee JH, Kim JM, Lee SY, Yoo S, Jung MK, et al. Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. *Mol Oncol* 2018;12:1203–15.

51. Zhou YJ, Guo YJ, Yang XL, Ou ZL. Anti-cervical cancer role of matrine, oxymatrine and sophora flavescens alkaloid gels and its mechanism. *J Cancer* 2018;9:1357–64.

52. Wang D, Cao Y, Zheng L, Lv D, Chen L, Xing X, et al. Identification of annexin A2 as a target protein for plant alkaloid matrine. *Chem Commun* 2017;53:5020–3.

53. Tian XY, Ma S, Tse G, Wong WT, Huang Y. Uncoupling protein 2 in cardiovascular health and disease. *Front Physiol* 2018;9:1060–73.

54. Blanc J, Alves-Guerra MC. Esposito B, Rousset S, Gourdy P, Ricquier D, et al. Protective role of uncoupling protein 2 in atherosclerosis. *Circulation* 2003;107:388–90.

55. Teshima Y, Akao M, Jones SP, Marban E. Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. *Circ Res* 2003;93:192–200.

56. Wang Y, Nishi M, Doi A, Shono T, Furukawa Y, Shimada T, et al. Ghrelin inhibits insulin secretion through the AMPK-UCP2 pathway in beta cells. *FEBS Lett* 2010;584:1503–8.

57. Liu L, Liu J, Tian XY, Wong WT, Lau CW, Xu A, et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. *Antioxid Redox Signal* 2014;21:1571–81.

58. Reilly JM, Thompson MP. Dietary fatty acids up-regulate the expression of UCP2 in 3T3-L1 preadipocytes. *Biochem Biophys Res Commun* 2000;277:541–5.

59. Samec S, Seydoux J, Dulloo AG. Interoorgan signaling between adipose tissue metabolism and skeletal muscle uncoupling protein homologs: is there a role for circulating free fatty acids?. *Diabetes* 1998;47:1693–8.

60. Donadelli M, Dando I, Fiorini C, Palmieri M. UCP2, a mitochondrial protein regulated at multiple levels. *Cell Mol Life Sci* 2014;71:1171–90.

61. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A, et al. AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. *J Mol Cell Cardiol* 2007;42:333–42.